Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Thelma Mashaka"'
Autor:
Kimberly Stegmaier, Jérôme Tamburini, Anthony Letai, Mark Wunderlich, Lynn H. Lee, Federica Piccioni, Scott T. Younger, Joseph D. Mancias, Jeremy A. Ryan, Biniam Adane, Sarah Mouche, Thelma Mashaka, Amy Saur Conway, Amanda L. Robichaud, Guillaume Kugener, Caroline S. Wechsler, Miljan Kuljanin, Neekesh V. Dharia, Bo Kyung A. Seong, Nastassja K. Scheidegger, Clément Larrue, Shan Lin
Supplementary Tables from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63a00231f66c2f1f2d618c874e239af4
https://doi.org/10.1158/2159-8290.22540225.v1
https://doi.org/10.1158/2159-8290.22540225.v1
Autor:
Kimberly Stegmaier, Jérôme Tamburini, Anthony Letai, Mark Wunderlich, Lynn H. Lee, Federica Piccioni, Scott T. Younger, Joseph D. Mancias, Jeremy A. Ryan, Biniam Adane, Sarah Mouche, Thelma Mashaka, Amy Saur Conway, Amanda L. Robichaud, Guillaume Kugener, Caroline S. Wechsler, Miljan Kuljanin, Neekesh V. Dharia, Bo Kyung A. Seong, Nastassja K. Scheidegger, Clément Larrue, Shan Lin
CRISPR–Cas9-based genetic screens have successfully identified cell type–dependent liabilities in cancer, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f8b74c36b48f4b32ecfaef81a5921cb
https://doi.org/10.1158/2159-8290.c.6549322
https://doi.org/10.1158/2159-8290.c.6549322
Autor:
Kimberly Stegmaier, Jérôme Tamburini, Anthony Letai, Mark Wunderlich, Lynn H. Lee, Federica Piccioni, Scott T. Younger, Joseph D. Mancias, Jeremy A. Ryan, Biniam Adane, Sarah Mouche, Thelma Mashaka, Amy Saur Conway, Amanda L. Robichaud, Guillaume Kugener, Caroline S. Wechsler, Miljan Kuljanin, Neekesh V. Dharia, Bo Kyung A. Seong, Nastassja K. Scheidegger, Clément Larrue, Shan Lin
Supplementary Data from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d609241f021048a4e574176ba23569
https://doi.org/10.1158/2159-8290.22540234
https://doi.org/10.1158/2159-8290.22540234
Autor:
Joseph D. Mancias, Amanda L. Robichaud, Jerome Tamburini, Clément Larrue, Federica Piccioni, Lynn Lee, Anthony Letai, Jeremy Ryan, Shan Lin, Amy Saur Conway, Nastassja K. Scheidegger, Mark Wunderlich, Scott T. Younger, Biniam Adane, Sarah Mouche, Neekesh V. Dharia, Guillaume Kugener, Bo Kyung A. Seong, Thelma Mashaka, Kimberly Stegmaier, Miljan Kuljanin, Caroline Wechsler
Publikováno v:
Cancer Discov
CRISPR–Cas9-based genetic screens have successfully identified cell type–dependent liabilities in cancer, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1c56bc6680b50eddcd2ed9826b4c7ab
Autor:
Robert J. Soiffer, Annette S. Kim, R. Coleman Lindsley, Haesook T. Kim, Anthony Letai, Mahasweta Gooptu, Corey Cutler, Thelma Mashaka, Vincent T. Ho, Jeremy Ryan, Jacqueline S. Garcia, Jennifer Brock, H. Moses Murdock, Richard Stone, Sarah Nikiforow, Hannah Q Karp, John Koreth, Fiona Loschi, Geoffrey Fell, Joseph H. Antin, Fabienne Lucas, Danielle S. Potter, Rizwan Romee, Roman M Shapiro, Daniel J. DeAngelo
Publikováno v:
Blood Advances
Key Points Adding venetoclax to FluBu2 reduced-intensity conditioning transplant did not impair engraftment or induce excessive graft-versus-host disease.Monitoring measurable residual disease by ultra-sensitive duplex sequencing revealed complex clo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0fa4a9e5ec675a59eb43639e81ce01c
https://pubmed.ncbi.nlm.nih.gov/34614506
https://pubmed.ncbi.nlm.nih.gov/34614506
Publikováno v:
Cell Death Differ
Inhibition of the anti-apoptotic machinery of cancer cells is a promising therapeutic approach that has driven the development of an important class of compounds termed “BH3 mimetics”. These novel small molecules mimic BH3-only proteins by antago
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b44eec846eb04da9e5f1515d7fbabb0e
https://doi.org/10.1038/s41418-019-0391-9
https://doi.org/10.1038/s41418-019-0391-9
Autor:
Amy Saur Conway, Miljan Kuljanin, Joseph D. Mancias, Sarah Mouche, Shan Lin, Scott T. Younger, Biniam Adane, Lynn Lee, Mark Wunderlich, Federica Piccioni, Amanda L. Robichaud, Jerome Tamburini, Guillaume Kugener, Bo Kyung A. Seong, Anthony Letai, Clement Larrue, Caroline Wechsler, Thelma Mashaka, Jeremy Ryan, Neekesh V. Dharia, Kimberly Stegmaier
CRISPR-Cas9-based genetic screens have successfully identified cell type-dependent liabilities in cancers, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea3b4a8acc172ebb9484c620b520f391
https://doi.org/10.1101/2020.12.28.424340
https://doi.org/10.1101/2020.12.28.424340
Autor:
Sophia Adamia, Shruti Bhatt, Marissa S. Piosos, Thelma Mashaka, Elyse A. Olesinski, Jeremy Ryan, Jacqueline S. Garcia, Buon Leutz, Anthony Letai, Binyam Yilma, David M. Weinstock
Publikováno v:
Cancer Research. 81:NG14-NG14
Relapse is the leading cause of treatment failure in acute myeloid leukemia (AML) patients. FDA approval of 8 targeted therapies in the past two years has drastically altered the landscape of AML treatment. Despite this success, the duration of clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8430de633fb95ec2118c05b796a6dda7
https://doi.org/10.1158/1538-7445.am2021-ng14
https://doi.org/10.1158/1538-7445.am2021-ng14
Autor:
Amy Han, Corey Cutler, Vincent T. Ho, Robert J. Soiffer, R. Coleman Lindsley, Sarah Nikiforow, Joseph H. Antin, Richard Stone, Thelma Mashaka, John Koreth, Jacqueline S. Garcia, Jeremy Ryan, Jennifer Brock, Anthony Letai, Mahasweta Gooptu, David P. Steensma, Martha Wadleigh, Haesook T. Kim, Daniel J. DeAngelo, Ilene Galinsky, Rizwan Romee
Publikováno v:
Blood. 134:258-258
Background: Patients (pts) with myeloid malignancies characterized by high risk mutations or cytogenetics who undergo allogeneic hematopoietic cell transplantation (HCT) have poor outcome primarily due to risk of relapse. Strategies to limit relapse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f16a0e8038a7f77df1c3436a102e030f
https://doi.org/10.1182/blood-2019-126172
https://doi.org/10.1182/blood-2019-126172
Publikováno v:
Biophysical Journal. 116:85a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8b22b1ad10b3961c33b36c98f781d67
https://doi.org/10.1016/j.bpj.2018.11.501
https://doi.org/10.1016/j.bpj.2018.11.501